Tertiary Nav - Press Releases Press ReleasesMedia Statements Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 11/1/23 Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments 10/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/30/23 Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy 10/25/23 Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results 9/29/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/7/23 Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year 9/7/23 Sarepta Therapeutics anuncia los destinatarios de la 6ª edición anual de Route 79, el programa de becas de Duchenne, para el año académico 2023-2024 9/5/23 Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference 8/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8/30/23 Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 21 - 30 of 813 Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Press Releases Items Per Page 102550 News Category Business & FinancialCitizenshipEarningsMedia StatementProduct NewsRecognitionRegulatoryScience & Innovation Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Date Title 11/1/23 Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments 10/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/30/23 Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy 10/25/23 Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results 9/29/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 9/7/23 Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year 9/7/23 Sarepta Therapeutics anuncia los destinatarios de la 6ª edición anual de Route 79, el programa de becas de Duchenne, para el año académico 2023-2024 9/5/23 Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference 8/31/23 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 8/30/23 Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 21 - 30 of 813